Kumar Patel, Vikash and Jena, Devashish and Kumar, Sandip (2025) Case Study of Atenolol. International Journal of Innovative Science and Research Technology, 10 (4): 25apr1162. pp. 2176-2180. ISSN 2456-2165

[thumbnail of IJISRT25APR1162.pdf] Text
IJISRT25APR1162.pdf - Published Version

Download (657kB)

Abstract

Atenolol, which is a cardioselective blocker of the beta-1 adrenergic receptors, is frequently used to treat hypertension, angina pectoris, and cardiac arrhythmias. The following is a case report of a 52-year-old man patient diagnosed with stage 2 hypertension (BP 168/102 mmHg) with a background history of exertional mild angina. Upon baseline assessment, the patient was started on Atenolol 50 mg daily. At 12-week follow-up, the patient demonstrated significant improvement in the control of blood pressure (mean BP lowered to 130/84 mmHg), reduction in the number of anginal attacks, and absence of serious side effects. Heart rate decreased from 88 bpm to 68 bpm with increased exercise tolerance. Slight fatigue was noticed in the initial period but subsided by the fourth week. The case highlights the ability of Atenolol to control both hypertension and accompanying angina, with an excellent safety profile in an outpatient environment. It is also underlines the need for individualized treatment, follow-up, and patient education on compliance and lifestyle change.

Item Type: Article
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine, Health and Life Sciences > School of Medicine
Depositing User: Editor IJISRT Publication
Date Deposited: 06 May 2025 09:15
Last Modified: 06 May 2025 09:15
URI: https://eprint.ijisrt.org/id/eprint/705

Actions (login required)

View Item
View Item